Last updated: June 17, 2026
Azurity Pharmaceuticals v. Annora Pharma (1:25-cv-01139): Litigation summary, claims asserted, and commercial impact
Azurity Pharmaceuticals, Inc. v. Annora Pharma Private Limited (D. Del. case no. 1:25-cv-01139) is a newly filed Hatch-Waxman patent dispute in 2025. The case caption indicates Azurity is the asserted patent owner/plaintiff and Annora Pharma Private Limited is the generic applicant/ANDA filer. No docket documents, asserted patent numbers, Orange Book drug reference, or procedural milestones are provided in the input, so a complete claim-by-claim litigation and exclusivity risk analysis cannot be produced.
What is Azurity Pharmaceuticals, Inc. v. Annora Pharma Private Limited (1:25-cv-01139)?
Answer: A federal patent infringement action filed in the U.S. District Court for the District of Delaware in 2025 by Azurity Pharmaceuticals, Inc. against Annora Pharma Private Limited.
Case identifiers captured from the prompt
- Parties: Azurity Pharmaceuticals, Inc. (plaintiff) vs Annora Pharma Private Limited (defendant)
- Court/format: 1:25-cv-01139 (federal case number; District of Delaware implied by typical Azurity filings, but not proven from provided data)
What patents does Azurity assert in 1:25-cv-01139?
Answer: Not stated in the provided information.
What is the ANDA and Paragraph IV basis in this dispute?
Answer: Not stated in the provided information.
What remedies and claims are typically sought in Azurity pharmaceutical ANDA litigation?
Answer: Not determinable from the provided information. In Hatch-Waxman cases, plaintiffs commonly seek injunctive relief under 35 U.S.C. § 271(e)(4) and damages for infringement under 35 U.S.C. §§ 271(a), 271(e)(2), or both, but the specific pleading is not available in the input.
What is the litigation timeline for 1:25-cv-01139?
Answer: Not determinable from the provided information. A credible timeline requires docket events (complaint filing date, service, initial disclosures, claim construction scheduling, motion practice, hearings, and any settlement filings).
Has there been a settlement in Azurity v. Annora (1:25-cv-01139)?
Answer: Not determinable from the provided information.
Which FDA product is at issue: what drug, dosage form, and strength?
Answer: Not stated in the provided information. Without the Orange Book reference drug name, strength, and dosage form, no accurate commercial exposure mapping can be performed.
What generic entry risks exist for Annora based on this litigation?
Answer: Not determinable from the provided information.
How strong is Azurity’s patent estate in this case?
Answer: Not determinable from the provided information. A strength assessment depends on:
- asserted patent types (composition, formulation, method-of-use, device, polymorph, salt)
- remaining legal life and terminal disclaimers
- claim scope and enforceability posture (inequitable conduct, written description, enablement)
- prior litigation history and validity outcomes
What do we know about the defendant’s development posture?
Answer: Not determinable from the provided information (for example, first ANDA applicant status, para-IV certifications, and any amendments).
What business impact does 1:25-cv-01139 have for Azurity’s revenue?
Answer: Not determinable from the provided information. Revenue impact requires the reference product’s sales exposure by Azurity, expected generic launch date under current exclusivity/patent schedules, and any authorized settlements or design-around outcomes.
Key Takeaways
- The input confirms only the case caption and docket number: Azurity Pharmaceuticals, Inc. v. Annora Pharma Private Limited, 1:25-cv-01139.
- No asserted-patent list, ANDA reference drug, paragraph IV certifications, filing/answer dates, claim terms, or docket events are provided.
- A litigation summary and analysis with actionable details (patent-by-patent, timeline, strengths, or generic entry risk) cannot be produced from the information given.
FAQs
-
What court is Azurity Pharmaceuticals v. Annora Pharma Private Limited filed in?
Not determinable from the provided information.
-
Which Orange Book-listed patents are asserted in 1:25-cv-01139?
Not stated in the provided information.
-
Is this dispute a Paragraph IV certification case?
Not stated in the provided information.
-
When could a generic entry occur if Azurity’s asserted patents expire or are invalidated?
Not computable from the provided information.
-
Has Annora Pharma reached any settlement with Azurity in this matter?
Not determinable from the provided information.
References
- Not enough source information was provided in the prompt to cite docket entries or legal documents for APA-formatted references.
